How many patients with Narcolepsy are under your care?

How many patients with Narcolepsy do you have on an Oxybate drug (Xyrem, Xywav, Lumryz) right now?

How many Narcolepsy patients do you currently have on the following treatments (please do not count IH patients in the figures below):

• Xyrem branded:
• Xyrem generic:
• Xywav:
•  Lumryz:

Of the [X] narcolepsy patients you currently have on Lumryz, how many of them:

• Are switches from Xyrem/Xywav?
• Are new Oxybate starts?

Of the [X] narcolepsy patients who are currently on an Oxybate:

• How many of those are NT1?
• How many of those are NT2?

Of the existing patients you currently have on Xyrem (both branded and generic) or Xywav, how many do you expect to switch to Lumryz (and stay on after switching) over the following time periods?

• Within the next 6 months:
• Within the next year/12 months:
• Within the next 2 years:

How many of the narcolepsy patients that you started over the past year on an oxybate drug for the first time in their life did you start with:

• Xyrem (generic or banded):
• Xywav:
• Lumryz:

How many of the narcolepsy patients that you expect to start over the next year on an oxybate drug for the first time in their life do you expect to start with:

• Xyrem (generic or banded):
• Xywav:
• Lumryz:

Of the new to oxybate narcolepsy patients that you have started on Xyrem or Xywav over the past 1-2 years, what percentage (%) of those patients DISCONTINUE TREATMENT at the following points in time (on a cumulative basis):

• After 1 month:
• After 3 months:
• After 12 months:

Of the new to oxybate narcolepsy patients that you have started on Lumryz over the past 1-2 years, what percentage (%) of those patients DISCONTINUE TREATMENT at the following points in time (on a cumulative basis):

• After 1 month:
• After 3 months:
• After 12 months:

For patients that were previously on Xyrem or Xywav but have attempted a switch to Lumryz over the past year, what percentage (%) of those patients DISCONTINUE LUMRYZ over the following points in time (on a cumulative basis):

• After 1 month:
• After 3 months:
• After 12 months:

For patients that have been on Xyrem or Xywav for over a year, what percentage % do you expect to DISCONTINUE over the next year ahead?

You currently have [X] narcolepsy patients on an oxybate drug right now. How many narcolepsy patients do you expect to have on an oxybate drug over the following periods of time:

• 1 year from now:
• 3 years from now:
• 5 years from now:

You currently have [X] patient(s) on Lumryz. How many total patients do you expect to have on Lumryz at the following points in time (please account for all sources of Lumryz starts and for the expected patient discontinuation rates):

• 1 year from now:
• 3 years from now:
• 5 years from now:

Please describe patient satisfaction with Lumryz compared to Xyrem or Xywav?

What are the biggest barriers, if any, that are holding back adoption of or persistence on Lumryz?

How would you compare the ease of prescribing and getting insurance coverage for Lumryz vs. Xyrem/Xywav:

• Much easier: 
• A little easier: 
• Equally easy: 
• A little harder: 
• Much harder:

Lumryz recently received approval from the FDA for pediatric use. How quickly do you expect pediatric patients to shift from Xyrem/Xywav to Lumryz in your practice and on a national basis?

On a scale 1-10 (where 1 is low and 10 is high) how excited are you about the potential benefits of Lumryz for your patients with narcolepsy?

How familiar are you with the emerging science and data on the Orexin agonists in general and on TAK860 and ALKS2680 specifically and how well or not they are likely to become compelling drugs to treat NT1 or NT2 in the next 5 years?

• Extremely familiar:
• Very familiar:
• Somewhat familiar:
• Not so familiar:
• Not at all familiar:

How many of the [X] NT1 patients on oxybate will go to Orexin Monotherapy and drop the oxybate after Orexins enter the market for NT1 (presumably TAK860)?/Display Logic = If familiar/

• In 1 year:
• In 3 years:

How many of the [X] NT2 patients on oxybate will go to Orexin Monotherapy and drop the oxybate after Orexins enter the market for NT2 (presumably ALKS2680)?
/Display Logic = If familiar/

• In 1 year:
• In 3 years: